Home  |  About the Book  |  Table of Contents  |  Search  |  Archive  |  Order  |  Visit JCO  |  Visit ASCO.org
ASCO Educational Book; 2009
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar content in this book
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reece, D.
Right arrow Articles by Gertz, M. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Reece, D.
Right arrow Articles by Gertz, M. A.

Nontransplant Therapy of Myeloma, High-dose Therapy for Myeloma, and a Personalized Care Plan for Treatment of Myeloma

Donna Reece, MD, Jean-Luc Harousseau, MD, and Morie A. Gertz, MD

From the Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada; Department of Medical Oncology, Centre René Gauducheau, Nantes Saint Herblain, Cedex France; and Department of Hematology, Mayo Clinic, Rochester, MN

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

Address reprint requests to Donna Reece, MD, Associate Professor and Director of the Program for Multiple Myeloma and Related Diseases, Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Avenue, Suite 5-207, Toronto, Ontario, Canada M5G 2M9; e-mail: donna.reece{at}uhn.on.ca

Overview: The landscape of myeloma therapy has changed radically since 1999. Novel agents resulting in prolongation of survival and better understanding of the biology of the disease have helped select patients most likely to benefit from stem cell transplantation. This review will provide an update on the latest data regarding the use of novel agents, discuss appropriate induction and maintenance therapy for transplant-appropriate patients, and will provide an algorithm for individualized patient care.